The new medicine is in development and could be our next best chance at thwarting Covid-19. This short-term, daily pill regimen can fight off the virus shortly after patient diagnosis, conceivably keeping systems from developing.
Timothy Sheahan, a virologist from the University of North Carolina-Chapel Hill, says, “Oral antivirals have the potential to not only curtail the duration of one’s covid-19 syndrome but also have the potential to limit transmission to people in your household if you are sick.”
When it comes to viral infections, such as HIV or hepatitis C, antivirals are some of the most effective treatments available to date.
Tamiflu is one of the most popular antivirals around. This often prescribed pill helps shorten influenza’s duration while reducing the chances of hospitalization if prescribed at the correct time.
Depending on the kind of medicine and how they developed, treating or preventing viral infections can vary. However, we know that they can boost the immune system so that it can fight off infection. An excellent antiviral can block healthy cell receptors so viruses can’t enter, and it can also lower the active virus population in the system.
Three current clinical trials are happening in which Covid-19 antivirals get tested. Carl Dieffenbach, director of the Division of AIDS at the National Institute of Allergy and Infectious Diseases, says that he’s expecting these medications to deliver results by the fall or winter of 2021.
Dieffenbach is the current overseers for antiviral development trials.
One of the top medicinal contenders, in this case, is a drug from Merck & Co. and Ridgeback Biotherapeutics known as Molnupiravir. The product is currently in testing at the Kellys’ Seattle Trial.
There are two others, including an antiviral from Roche and Atea Pharmaceuticals and PF-08321332, a Pfizer candidate.
These antivirals interfere with the Covid-19 virus’ ability to replicate with the body’s cells. Molnupiravir, however, copies genetic materials from the virus with so many mistakes that it is not able to reproduce. Therefore, it shortens infection time and prevents a particularly deadly immune system response.
Remdesivir is the unique antiviral drug that has reached the level of COVID treatment approval. As of now, it is only given to Covid patients in the hospital intravenously and not intended for widespread or preventative use. This antiviral is far different from the top antiviral developments, packed and delivered in pill form.
Though these antivirals got initially ignored due to lack of interest, Covid-19 infections are at the center of funding and competition. The Biden Administration announced back in June that it wanted to obtain 1.7 million Molnupiravir treatments for $1.2 billion given the product receives full approval or emergency authorization.
According to Dieffenbach, back in June, the Biden administration said it was planning on investing $3.2 billion in the Antiviral Program for Pandemics. This unique program’s goal is to develop Covid-19 antivirals.
A Daily Pill To Treat COVID Could Be Just Months Away …. https://health.wusf.usf.edu/health-news-florida/2021-09-24/a-daily-pill-to-treat-covid-could-be-just-months-away-scientists-say